NIKKEI 225
38,356.06 +176.60 (+0.46%) HANG SENG
19,073.71 -41.35 (-0.22%) CRUDE OIL
78.45 -0.67 (-0.85%) GOLD FUTURES
2,363.50 +20.50 (+0.87%) DOW
39,558.11 +126.60 (+0.32%) Bitcoin GBP
48,821.84 -1,213.67 (-2.43%)
NVO Jul 2024 65.000 call
| Previous close | 65.30 |
| Open | 65.30 |
| Bid | 56.30 |
| Ask | 61.00 |
| Strike | 65.00 |
| Expiry date | 2024-07-19 |
| Day's range | 65.30 - 65.30 |
| Contract range | N/A |
| Volume | |
| Open interest | 3 |
BloombergOzempic Maker Novo Sells $5 Billion in Bonds to Fund Deal
(Bloomberg) -- Novo Nordisk A/S is selling €4.65 billion ($5 billion) in bonds to fund plans to ramp up production of its blockbuster drugs, drawing high investor demand for its first debt issuance in more than two years.Most Read from BloombergTrump Vows ‘Day One’ Executive Order Targeting Offshore WindBiden Accuses China of ‘Cheating’ on Trade, Imposes New TariffsFlood of China Used Cooking Oil Spurs Call to Hike US LeviesMacron Puts French Banks in Play With Plan to Transform EuropeHow One of
ZacksNovo Nordisk (NVO) Up 3% as Haemophilia Drug Meets Study Goals
Novo Nordisk's (NVO) shares rise 3.1% as the company meets co-primary endpoints in a late-stage study evaluating its investigational candidate, Mim8, for the treatment of haemophilia A.
ZacksHere's Why Novo Nordisk (NVO) is a Strong Growth Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
